ES2566602T3 - Anticuerpos anti-ErbB3 - Google Patents

Anticuerpos anti-ErbB3 Download PDF

Info

Publication number
ES2566602T3
ES2566602T3 ES11722942.7T ES11722942T ES2566602T3 ES 2566602 T3 ES2566602 T3 ES 2566602T3 ES 11722942 T ES11722942 T ES 11722942T ES 2566602 T3 ES2566602 T3 ES 2566602T3
Authority
ES
Spain
Prior art keywords
seq
sh24c05
kappa
heavy
igg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11722942.7T
Other languages
English (en)
Spanish (es)
Inventor
Sylvie Vincent
William M. Winston, Jr.
Fang Wang
Solly Weiler
Kristan Meetze
Lyne Breault
Steve Bottega
Ting Chen
Michael Deprima
Christina Fleet
Steven Tyler
Jin-Kyeung Woo
Jeno Gyuris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2566602T3 publication Critical patent/ES2566602T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11722942.7T 2010-04-09 2011-04-08 Anticuerpos anti-ErbB3 Active ES2566602T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US322712P 2001-09-17
US32271210P 2010-04-09 2010-04-09
PCT/US2011/031829 WO2011136911A2 (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Publications (1)

Publication Number Publication Date
ES2566602T3 true ES2566602T3 (es) 2016-04-14

Family

ID=44120965

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11722942.7T Active ES2566602T3 (es) 2010-04-09 2011-04-08 Anticuerpos anti-ErbB3

Country Status (18)

Country Link
US (6) US8481687B2 (https=)
EP (1) EP2566895B1 (https=)
JP (1) JP5906233B2 (https=)
KR (1) KR101764453B1 (https=)
CN (2) CN105968206B (https=)
AR (1) AR080873A1 (https=)
AU (1) AU2011245636B2 (https=)
BR (1) BR112012025730B1 (https=)
CA (1) CA2795799C (https=)
ES (1) ES2566602T3 (https=)
IL (1) IL222272B (https=)
MX (1) MX343227B (https=)
NZ (1) NZ603271A (https=)
PH (1) PH12012502022B1 (https=)
RU (1) RU2568051C2 (https=)
SG (1) SG184452A1 (https=)
WO (1) WO2011136911A2 (https=)
ZA (1) ZA201208290B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
JP6169085B2 (ja) 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
DK2797957T3 (da) * 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
EP3590538A1 (en) * 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
CN104105709A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 抗her3的结构域ii的表皮生长因子受体3(her3)抗体
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10538591B2 (en) * 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
CA2941029C (en) * 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN104861068B (zh) * 2015-01-23 2020-11-17 中国人民解放军军事科学院军事医学研究院 一种全人源抗her3抗体及其治疗相关疾病的用途
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA3000531A1 (en) * 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
HK1258375A1 (zh) * 2015-11-24 2019-11-08 Onk Therapeutics Limited 人源化抗-cll-1抗体
KR101746152B1 (ko) 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
US11155617B2 (en) 2016-06-23 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
CN106692969B (zh) * 2016-12-08 2021-08-10 北海康成（北京）医药科技有限公司 抗erbb3抗体及其用途
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
SG11201908744PA (en) * 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
CN113683700B (zh) * 2017-06-22 2023-05-02 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
MX2020002612A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
CN111094339B (zh) * 2017-10-17 2023-01-24 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
GB201804094D0 (en) 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CN116744971A (zh) * 2021-01-04 2023-09-12 上海翰森生物医药科技有限公司 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
KR20240137086A (ko) 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物
CN115806619A (zh) * 2022-10-09 2023-03-17 苏州市立医院 一种单克隆抗体及其用途
EP4637821A1 (en) * 2022-12-23 2025-10-29 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
CN118005795B (zh) * 2024-04-09 2024-06-28 天津旷博同生生物技术有限公司 一种抗人cd64抗体及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69736806T3 (de) * 1996-03-27 2015-10-08 Genentech, Inc. ErbB3 ANTIKÖRPER
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR101598229B1 (ko) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
EP2425009A4 (en) 2009-04-29 2013-01-23 Trellis Bioscience Llc Improved antibodies immunoreactive with heregulin-coupled her3
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
AU2010303443A1 (en) 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
CA2813796C (en) * 2010-10-18 2019-01-15 Mediapharma S.R.L. Erbb3 binding antibody
JP6169085B2 (ja) * 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定

Also Published As

Publication number Publication date
BR112012025730B1 (pt) 2020-12-08
CN105968206B (zh) 2020-01-17
KR20130043106A (ko) 2013-04-29
WO2011136911A3 (en) 2012-03-08
US11680108B2 (en) 2023-06-20
ZA201208290B (en) 2013-07-31
US20110256154A1 (en) 2011-10-20
US9598498B2 (en) 2017-03-21
BR112012025730A2 (pt) 2017-01-10
US12486332B2 (en) 2025-12-02
JP5906233B2 (ja) 2016-04-20
US9228021B2 (en) 2016-01-05
MX2012011718A (es) 2012-12-17
CN102884085B (zh) 2016-08-03
US20230365710A1 (en) 2023-11-16
US20180030149A1 (en) 2018-02-01
IL222272B (en) 2018-04-30
AU2011245636A2 (en) 2012-11-29
PH12012502022B1 (en) 2019-03-08
US10494441B2 (en) 2019-12-03
AR080873A1 (es) 2012-05-16
JP2013523166A (ja) 2013-06-17
US20130330772A1 (en) 2013-12-12
IL222272A0 (en) 2012-12-31
CN102884085A (zh) 2013-01-16
HK1178184A1 (zh) 2013-09-06
EP2566895A2 (en) 2013-03-13
CA2795799A1 (en) 2011-11-03
NZ603271A (en) 2014-05-30
PH12012502022A1 (en) 2013-01-21
US20200299406A1 (en) 2020-09-24
SG184452A1 (en) 2012-11-29
US8481687B2 (en) 2013-07-09
RU2012147591A (ru) 2014-05-20
US20160264679A1 (en) 2016-09-15
KR101764453B1 (ko) 2017-08-02
CN105968206A (zh) 2016-09-28
MX343227B (es) 2016-10-28
EP2566895B1 (en) 2015-12-30
WO2011136911A2 (en) 2011-11-03
RU2568051C2 (ru) 2015-11-10
BR112012025730A8 (pt) 2017-05-23
CA2795799C (en) 2018-09-25
AU2011245636B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
ES2566602T3 (es) Anticuerpos anti-ErbB3
KR102031020B1 (ko) 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
ES2593754T3 (es) Anticuerpos anti-IL-23
US20250289884A1 (en) Anti-notch3 antibodies
JP2020504627A (ja) 抗ｐｄ−１抗体及びその使用
US20260042850A1 (en) Anti c-met antibodies
JP2018538368A (ja) 抗５ｔ４抗体および抗体−薬物コンジュゲート
JP2013533746A (ja) 抗ｒｏｎ抗体
WO2011156617A2 (en) Anti-egfr antibodies
CN117769434A (zh) 与C1s结合的抗体和其用途
US20250129176A1 (en) Cd19/cd38 multispecific antibodies
CA3091307A1 (en) Csf1r binding agents
CN119584995A (zh) 组合疗法
JP7611894B2 (ja) 抗体およびその抗原結合フラグメントの機能的な親和性を高めるための修飾されたＦｃ領域
WO2024074498A1 (en) Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2022216672A1 (en) Anti-annexin a1 antibodies
HK1178184B (en) Anti-erbb3 antibodies